32 completed, 15 unknown, 7 terminated, 2 recruiting. 18 Phase 2, 11 Phase 3, 6 Phase 1, 4 Not applicable, 4 Phase 4.
Follow Pemphigoid, Bullous: new trials by email Literature Review of Pemphigoid, Bullous trials Research Report on Pemphigoid, Bullous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Association Between Disease Severity and Clinical, Histopathological, and Eosinophilic Markers in Patients With Bullous Pemphigoid (BP-EPIC) Bullous Pemphigoid (BP) | Active not recruiting | Istanbul Training and Research Hospital | 50 | 2026-05-04 | 2026-06-16 | |
| Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid Stapokibart injection, Placebo - Bullous Pemphigoid (BP) | Phase 3 | Not yet recruiting | Chengdu Kangnuoxing Biopharma,Inc. | 200 | 2025-11-11 | 2025-10-07 |
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Enrolling by invitation | Chugai Pharmaceutical | 144 | 2024-12-09 | 2026-07-17 |
| Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Recruiting | Chugai Pharmaceutical | 144 | 2024-08-19 | 2026-07-22 |
| Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis This is a retrospective analysis of health data from inpatient record, no intervention was designed - Bullous Pemphigoid | Unknown | Xijing Hospital | 318 | 2024-01-11 | 2024-01-19 | |
| Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP) clobetasol decreasing measurement - Pemphigoid, Bullous, Adrenal Insufficiency | Not applicable | Unknown | University Hospital, Bordeaux | 50 | 2024-01-04 | 2024-02-20 |
| Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid Prednisolone, Dapsone, Methotrexate - Bullous Pemphigoid | Phase 4 | Completed | All India Institute of Medical Sciences, Bhubaneswar | 62 | 2023-08-01 | 2025-08-14 |
| A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid efgartigimod PH20 SC, Prednisone - Bullous Pemphigoid | Phase 3 | Terminated | argenx | 64 | 2023-03-22 | 2026-02-25 |
| Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 20 | 2022-11-11 | 2024-07-08 |
| Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid Ozonated olive oil, Topical garamycin cream - Pemphigus Vulgaris, Bullous Pemphigoid | Phase 3 | Unknown | Cairo University | 30 | 2022-11-01 | 2022-11-08 |
| Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid Dupilumab - Bullous Pemphigoid | Completed | Peking University First Hospital | 146 | 2022-09-01 | 2023-12-04 | |
| Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid IGA score, BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI) - Bullous Pemphigoid | Unknown | University Hospital, Rouen | 150 | 2022-07-01 | 2022-05-09 | |
| A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid efgartigimod PH20 SC, placebo, Prednisone - Bullous Pemphigoid | Phase 2 / Phase 3 | Completed | argenx | 98 | 2022-06-09 | 2025-10-23 |
| Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) nomacopan (rVA576), Placebo - Bullous Pemphigoid | Phase 3 | Withdrawn | AKARI Therapeutics | 2022-05-06 | 2025-04-09 | |
| Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid Blood sampling, Liquid bubble sampling, Cutaneous biopsy - Bullous Pemphigoid | Not applicable | Unknown | CHU de Reims | 140 | 2022-02-10 | 2024-06-27 |
| JAK Inhibitors' Efficacy in Bullous Pemphigoid Janus Kinase Inhibitor - Bullous Pemphigoid, Janus Kinase Inhibitor | Completed | Chao Ji | 120 | 2022-01-01 | 2024-09-05 | |
| A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. Benralizumab, Placebo - Bullous Pemphigoid | Phase 3 | Terminated | AstraZeneca | 67 | 2021-03-31 | 2024-11-29 |
| Telederm and Bullous Pemphigoid Bullous Pemphigoid | Completed | Emory University | 21 | 2021-03-15 | 2023-10-13 | |
| Study of the Periodontal Microbiota in Gingival Cicatricial Pemphigoid Patients. Bicentric Pilot Study. Collection of subgingival dental plaque - Pemphigoid | Completed | Centre Hospitalier Universitaire de Nice | 24 | 2021-01-19 | 2023-11-18 | |
| Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid bone densitometry, blood test, radiographs of the thoracic and lumbar spine - Osteoporosis, Bullous Pemphigoid | Phase 4 | Completed | Centre Hospitalier Universitaire, Amiens | 50 | 2020-12-11 | 2026-09-08 |
Showing 20 of 62. Sign in to see all of them.
Pemphigus (5) · Pruritus (5) · Skin Diseases (4) · Autoimmune Diseases (3) · Blister (3) · Antiphospholipid Syndrome (2) · Behcet Syndrome (2) · Dermatomyositis (2) · Eosinophilia (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Stevens-Johnson Syndrome (2) · Adrenal Insufficiency (1) · Anemia, Hemolytic, Autoimmune (1) · Blindness (1)
Skin Diseases, Vesiculobullous (62) · Skin and Connective Tissue Diseases (62) · Immune System Diseases (61) · Autoimmune Diseases (59) · Skin Diseases (58) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (8) · Skin Manifestations (7) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Mouth Diseases (4) · Pathologic Processes (4) · Stomatognathic Diseases (4) · Connective Tissue Diseases (3) · Eye Diseases (3)
Blood Specimen Collection (4) · Prednisone (4) · Clobetasol (3) · Methotrexate (3) · Rituximab (3) · dupilumab (3) · Omalizumab (2) · 2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide (1) · Adrenal Cortex Hormones (1) · Azathioprine (1) · Dapsone (1) · Dipeptidyl-Peptidase IV Inhibitors (1) · Doxycycline (1) · Electronic Health Records (1) · Hematologic Tests (1)
CHU de Reims (6) · University Hospital, Rouen (5) · AKARI Therapeutics (2) · Centre Hospitalier Universitaire de Nice (2) · Chugai Pharmaceutical (2) · Nihon Pharmaceutical Co., Ltd (2) · Regeneron Pharmaceuticals (2) · argenx (2) · Alexion Pharmaceuticals, Inc. (1) · Alkahest, Inc. (1) · All India Institute of Medical Sciences, Bhubaneswar (1) · Assistance Publique Hopitaux De Marseille (1) · AstraZeneca (1) · Bioverativ, a Sanofi company (1) · Brigham and Women's Hospital (1)
France (27) · United States (15) · Germany (12) · Japan (9) · China (7) · Netherlands (7) · Spain (7) · Australia (6) · Italy (6) · Taiwan (6) · Bulgaria (5) · Israel (5) · Poland (5) · Austria (4) · Croatia (4)
Aaron Mangold, MD (1) · Aikaterini Kountouri, MD (1) · Andrea Kneisel, MD (1) · Anne Pham-Ledard, MD, PhD (1) · Ayse Esra Koku Aksu, Prof.Dr. (1) · Benjamin Batteux, MD (1) · Biagio Didona, MD (1) · Catherine Lok, Pr (1) · Chao Ji, PhD (1) · Craig A Elmets (1)
PMID 18087004, PMID 27716293, PMID 28926521, PMID 28980446, PMID 30559259, PMID 30837635, PMID 35507334, PMID 38443648, PMID 38508975, PMID 38995690, PMID 39310808, PMID 41807108
2014 (2), 2019 (1), 2023 (1), R01AR076089 (1)